帕博利珠单抗联合含铂化疗治疗多形性肺癌。
Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung.
机构信息
Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
出版信息
In Vivo. 2020 May-Jun;34(3):1439-1443. doi: 10.21873/invivo.11926.
BACKGROUND/AIM: Pleomorphic carcinoma of the lung is a rare, highly malignant subtype of lung cancer, with a more aggressive clinical course compared with other types of non-small-cell lung cancer (NSCLC). Platinum-containing chemotherapy has been the standard therapy for patients with NSCLC and pembrolizumab is one of the novel and reliable agents for these patients.
CASE REPORT
We herein report the case of a 60-year-old man with advanced chemo-naïve pleomorphic carcinoma of the lung who was successfully treated with a combination of pembrolizumab with platinum-containing chemotherapy.
CONCLUSION
In the absence of definitive clinical trials, which are unlikely to be performed due to the rarity of this tumor, our case demonstrates the potential utility of the combination of pembrolizumab with platinum-containing chemotherapy. Our result also suggest that this combination of therapy may be key to the treatment of pleomorphic carcinoma of the lung.
背景/目的：肺多形性癌是一种罕见的、高度恶性的肺癌亚型，与其他非小细胞肺癌（NSCLC）相比，其临床病程更具侵袭性。含铂化疗一直是 NSCLC 患者的标准治疗方法，而帕博利珠单抗是这些患者的新型可靠药物之一。
病例报告
我们在此报告一例 60 岁男性，患有晚期初治肺多形性癌，该患者接受了帕博利珠单抗联合含铂化疗的成功治疗。
结论
由于这种肿瘤罕见，不太可能进行明确的临床试验，因此在没有临床试验的情况下，我们的病例证明了帕博利珠单抗联合含铂化疗的潜在效用。我们的结果还表明，这种联合治疗可能是治疗肺多形性癌的关键。
Zotero 插件